Overexpression of P53 protein and local hGH, IGF-I, IGFBP-3, IGFBP-2 and PRL secretion by human breast cancer explants by Milewicz, Tomasz et al.
PE
RS
ON
AL
 U
SE
 
CO
PY
Th
is 
co
py
 is
 fo
r p
er
so
na
l u
se
 o
nl
y 
- d
ist
rib
ut
io
n 
is 
pr
oh
ib
ite
d.
   
  T
hi
s c
op
y 
is 
fo
r p
er
so
na
l u
se
 o
nl
y 
- d
ist
rib
ut
io
n 
is 
pr
oh
ib
ite
d.
   
  T
hi
s c
op
y 
is 
fo
r p
er
so
na
l u
se
 o
nl
y 
- d
ist
rib
ut
io
n 
is 
pr
oh
ib
ite
d.
   
  T
hi
s c
op
y 
is 
fo
r p
er
so
na
l u
se
 o
nl
y 
- d
ist
rib
ut
io
n 
is 
pr
oh
ib
it
To cite this article: Neuroendocrinol Lett 2011; 32(3):328–333
O
R
I
G
I
N
A
L
 
A
R
T
I
C
L
E
Neuroendocrinology Letters Volume 32 No. 3 2011
Overexpression of P53 protein and local 
hGH, IGF-I, IGFBP-3, IGFBP-2 and PRL 
secretion by human breast cancer explants 
Tomasz Milewicz 1, Janusz Ryś 2, Anna Wójtowicz 6, Ewa Stochmal 4, Robert Jach 5, 
Józef Krzysiek 1, Ewa Gregoraszczuk 3, Hubert Huras 6, Olivia Dziadek 5
1  Departament of Gynecological Endocrinology, Collegium Medicum, Jagiellonian University, Cracow, 
Poland 
2  Department of Pathology, Cracow Branch of Institute of Oncology, Cracow, Poland 
3  Laboratory of Physiology and Toxicology of Reproduction, Dept of Animal Physiology, Institute of 
Zoology, Jagiellonian University, Cracow, Poland 
4  Department of Human Developmental Biology, Collegium Medicum, Jagiellonian University, 
Cracow, Poland 
5  Departament of Gynecological Oncology, Collegium Medicum, Jagiellonian University, Cracow, Poland
6  Depratment of Obstetrics and Perinatology, Collegium Medicum, Jagiellonian University, Cracow, 
Poland
Correspondence to: Tomasz Milewicz, MD., PhD.
Department of Gynecological Endocrinology, Jagiellonian University, 
23 Kopernika Str., 31-501 Cracow, Poland.
tel: +48 4248412; e-mail: milewicz@interia.eu
Submitted: 2011-04-10 Accepted: 2011-05-12 Published online: 2011-06-29
Key words:  P53;  hGH;  IGF family;  prolactin;  breast cancer 
Neuroendocrinol Lett 2011; 32(3):328–333 PMID: 21670726  NEL320311A07 © 2011 Neuroendocrinology Letters • www.nel.edu
Abstract BACKGROUND: Insulin-like growth factor-I (IGF-I) in concert with insulin-like 
binding protein 3 (IGFBP-3), insulin-like binding protein 2 (IGFBP-2), human 
growth hormone (GH) and P53 protein is involved in autocrine/paracrine growth 
signaling pathways as an adaptive response to environmental stimuli. OBJECTIVE: 
The study evaluated the local secretion of PRL, hGH, IGF-I, IGFBP-2 and IGFBP-3 
by breast cancer tissue explants in relation to the overexpression of P53 protein 
in breast cancer tissue. MATERIALS AND METHODS: Breast cancer explants were 
obtained during radical mastectomies. The overexpression of P53 protein was 
assessed immunohistochemically using monoclonal antibody (DAKO, Anti-Human 
P53 protein, clone DO-7); the results of the reaction were stratified into 5 groups. 
The lack of P53 protein overexpression was defined as 0% of cells that overexpressed 
P53 protein. IGF-I, IGFBP-3, IGFBP-2, and hGH levels were measured with RIA 
kits, and prolactin was measured with the MEIA kit. RESULTS: The local secretion 
of hGH by tumour explants – presenting a positive immunohistochemical reaction 
(IHCR) to the product of P53 gene – was twice as high as those with no IHCR to 
product of P53 gene; the opposite was noted in the case of IGF-I, IGFBP-2 and 
IGFBP-3 secretion. In both cases, the level of hGH, IGF-I and IGFBP-3 secretion 
did not correlate with the ratio of cells overexpressing P53 protein. There was a 
significant decrease in local, basic IGFBP-2 secretion along with an increased ratio 
of cells with positive IHCR to product of P53 gene. Furthermore, local PRL secre-
tion was not correlated with the ratio of cells overexpressing P53 protein in breast 
cancer tissue. Prolactin also exerts no influence on IGF-I secretion. CONCLUSION: 
Our results may suggest the presence of local hGH/IGF-I feedback in breast tissue 
as well as the possibility of P53/hGH/IGF-I/IGFBP-3 but not P53/PRL/IGF-I axis. 
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INTRODUCTION
Cellular survival and proliferation can be positively 
regulated through the action of cytokines. The signal-
ing effects of P53 and cytokines on the cellular pheno-
type are counteracting (Fritsche et al. 1998). Tumour 
suppressor genes function as the specific inhibitors of 
tumour cell growth. Inhibition of tumour cell prolifera-
tion by P53 is exerted by means of activation of tumour 
cell differentiation (Li et al. 1998). Tumour suppres-
sor P53 is a phosphoprotein barely detectable in the 
nucleus of normal cells and is also regarded as a nuclear 
transcription factor that inhibits cell cycle progression 
and induces apoptosis (Fritsche et al. 1998; Benchimol 
et al. 1982; Ryan & Vousden 1998; Werner et al. 1996). 
P53 gene is the single most important human tumour 
suppressor that is commonly affected by mutations in 
human malignancies including breast cancer (Werner 
et al. 1996; Grimberg 2000). Experimental data has 
shown that cells containing the wild-type P53 gene 
undergo death by apoptosis after anticancer treatment, 
whereas cells that lack wild-type P53 gene show resis-
tance to drugs (Lowe et al. 1993). In times of cellular 
stress, wild-type P53 gene can arrest cell cycle progres-
sion, thereby allowing DNA to be repaired (Kastan et 
al. 1991). If the damage is beyond cell repair capability, 
the P53 protein diverts the fate of the cell into apoptosis 
(Ferreira et al. 1999). Wild type P53 tumour suppressor 
is a crucial mediator of apoptosis in response to cellular 
stress (Butt et al. 1999). According to Niezabitowski et 
al. p53 protein may be considered one of the indepen-
dent prognostic parameters for disease free survival of 
patients with phyllodes tumour of the breast (Niezabi-
towski et al. 2001). The College of American Patholo-
gists included the p53 gene and its protein product in the 
group of breast cancer prognostic factors, which should 
be investigated intensively (Fitzgibbons, et al. 2000).
The mode of activation of many tumor suppressor 
genes involves transcriptional suppression of IGF-I 
receptor gene with subsequent reduction of cell sur-
face receptor concentration and IGF-I action. A loss 
of function mutation of tumor suppressors can lead to 
aberrant regulation of IGF-I receptor gene expression 
(Werner & Maor 2006). p53 gene apoptotic action is 
exerted via manipulation of insulin-like growth factor 
(IGF) axis components (Grimberg 2000). Wild type P53 
gene induction causes the down-regulation of mem-
brane IGF-I receptor. The mutant form of P53 gene is 
important for up-regulation of the receptor (Girnita 
et al. 2000). IGF-I in concert with insulin-like binding 
protein-3 and P53 is involved in autocrine/paracrine 
growth signaling pathways as adaptive responses to 
environmental stimuli (Kari et al. 1999). Webster et al. 
and Ohlsson et al. found a positive correlation between 
expression of P53 and IGF-I receptor expression (Web-
ster et al. 1996; Ohlsson et al. 1998). Transcriptional 
activation of IGF-I receptor gene requires an intact P53 
signaling pathway (Glait et al. 2006). The addition of 
IGF-I to in vitro mouse mammary gland whole organ 
culture − that was exposed to estrogen and progesterone 
− inhibited cell death and expression of P53 (Mathews 
& Schneider 2008).
Carcinogenesis involves an accumulation of spe-
cific molecular alterations occurring in specific proto-
oncogenes or tumour suppressor genes. Rapid cellular 
turnover may increase the rate at which the alterations 
accumulate. The IGF axis is one of the determinants 
of cellular turnover rate (Baserga 1995). Appropriate 
levels of P53 activity are important to the regulation of 
mammary gland ductal morphogenesis in part through 
regulation of the IGF-I pathway (Gatza et al. 2008). The 
insulin-like growth factors and its binding proteins 
have been disturbed in breast cancer (Landberg et al. 
2001). The mutant form of P53 gene loses its apoptotic 
activity and ability to activate transcription from the 
P53 protein responsive portion of Insulin-like growth 
factor binding protein-3 (IGFBP-3) gene promoters 
(Friedlander et al. 1996). IGFBP-3 inhibits cell growth 
and enhances apoptosis not only by limiting the avail-
ability of IGF-I to its receptors but also independently 
by its own receptors (Hollowood et al. 2000; Oh 1998). 
The presence of IGF/P53 axis may be suggested (Web-
ster et al. 1996).
Our previous studies showed the local secretion 
of hGH, IGF-I and prolactin by human breast cancer 
explants. Moreover, the studies demonstrated that hGH 
stimulates local IGF-I secretion by human breast cancer 
explants expressing progesterone receptors. Progester-
one induced the decrease of IGFBP-3 secretion in the 
same type of malignant explants. Therefore, it seemed 
interesting to evaluate the relationship between local 
PRL, hGH and IGF-I secretion from human breast 
cancer explants and the expression of the P53 protein 
mutant form. 
MATERIALS AND METHODS
Tissues
Breast cancer explants were obtained during 48 radi-
cal mastectomies performed at the Cracow Branch 
of National Institute of Oncology Cracow, Poland. 
Explants of malignant tissue were prepared under close 
supervision of a pathologist, eliminating the hazard 
of interfering with further pathologic evaluation of a 
malignant lesion of the breast. Some of the specimens 
were fixed in 10% buffered formalin for 48 hours at 
room temperature, dehydrated and embedded in paraf-
fin by a standard procedure. A section 5-μm thick was 
mounted on slides and deparaffinated before process-
ing for receptor determination by immunohistochem-
istry. The overexpression of P53 protein was evaluated 
by monoclonal antibodies from commercial kits manu-
factured by the DACO Company (DAKO, Anti-Human 
p53 protein, clone DO-7). The results of the evaluation 
were stratified into 5 groups: lack of P53 overexpression 
(0% of cells immunohistochemically positive to P53), 
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weak positive overexpression (0–10% of cells immuno-
histochemically positive to P53), moderate overexpres-
sion (10–50% of cells immunohistochemically positive 
to P53), strong overexpression (50–80% of cells immu-
nohistochemically positive to P53) and very strong 
overexpression (80–100% cells immunohistochemi-
cally positive to P53).
Mammary gland in vitro incubation
Primary tumour explants were prepared according to 
Gregoraszczuk. Briefly, remaining explants from the 
malignant tissue and surrounding non-malignant tissue 
were trimmed into 0.5 cm3 pieces, weighed and incu-
bated in 2 ml of M199 medium containing 5% of calf 
serum. Afterward, results obtained by means of immu-
nohistochemistry were matched to those from culture. 
Four explant pieces obtained from each malignant 
tissue of each individual patient were put into culture 
tubes and incubated for 48hrs in a medium. Experimen-
tal tubes with explants were shaken gently at 37 °C. The 
media was continuously gassed with 5% C02 /air during 
incubation. After 48 hours incubation, the collected 
media were frozen at –20 °C for evaluation of hGH, 
PRL, IGF-I, IGFBP-3 and IGFBP-2 level in the media.
Hormone concentration evaluation
IGF-I level was measured, using Biosource Europe 
S.A. RIA kits sensitivity 0.25 ng/ml; the coefficients 
of variation within and between assays were 4.1% and 
9.3% respectively; cross reaction, with insulin 0.001%, 
with hGH 0.01%, and with IGF-II 0.2%. Human 
growth hormone (hGH) level was estimated with 
OBRI POLATOM (Świerk, Poland), RIA kits: sensitiv-
ity 0.5 ng/ml, the coefficients of variation within, and 
between, assays were 2.1% and 2.7% respectively. For 
prolactin assessment an Abbot Lab MEIA (Microparti-
cle Enzyme Immunoassay) kit was used: sensitivity 0.6 
ng/ml, cross reaction with hGH 0.039%, and no cross 
reaction with FSH, LH, TSH, hCG, hPL.
IGFBP-3 level was measured by RIA kits manufac-
tured by Diagnostic Systems Laboratories, Webster, 
Texas, USA. The sensitivity was 0.5 ng/ml, whereas 
the specificity was 99%. IGFBP-2 level was evaluated 
also by RIA kits manufactured by Diagnostic Systems 
Laboratories, Webster, Texas, USA. The sensitivity was 
0.5 ng/ml, whereas the specificity was 99%. No cross 
reactivity was found with hGH, IGF-I, IGF-II, IGFBP-
3, IGFBP-4, IGFBP-5, IGFBP-6.
IGFBP-2 level was measured by RIA kits manufac-
tured by Diagnostic Systems Laboratories, Webster, 
Texas, USA. The sensitivity was 0.5 ng/ml, whereas 
the specificity was 99%. No cross reactivity was found 
with hGH, IGF-I, IGF-II, IGFBP-3, IGFBP-4, IGFBP-5, 
IGFBP-6.
Statistical methods
All data points are expressed as means ± SEM. A signif-
icant difference in hGH, prolactin, IGF-I, IGFBP-3 and 
IGFBP-2 levels in malignant tissue also showed diverse 
overexpression of P53; comparison was made by analy-
sis of variance and Duncan’s new multiple range test. 
RESULTS
The lowest [p<0.01] secretion of hGH was found in 
explants with a lack of cells showing positive immu-
nohistochemical reaction (IHCR) to P53 protein 
[0.18±0.04 ng/10mg tissue]. Explants with various rates 
of cells showing positive IHCR to P53 protein showed 
higher secretion of hGH but without significant dif-
ferences between groups of P53 overexpression levels 
[0.54±0.02 ng/10 mg tissue; 0.51±0.1 ng/10 mg tissue; 
0.54±0.05 ng/10mg tissue; 0.61±0.1 ng/10mg tissue 
respectively in 0–9.9%; 10–49.9%; 50–79.9%; 80–100% 
of cells with positive IHCR for P53 protein (Figure 1).
The highest local IGF-I secretion was observed in 
explants with a lack of immunohistochemical reaction 
(IHCR) to P53 protein. The secretion by explants mir-
rored in a way the hGH secretion pattern. The explants, 
which showed negative IHCR to P53 protein, secreted 
the highest amount of IGF-I [24.14.0; 24.91.9ng/10 
mg tissue]. The explants which showed positive IHCR 
to P53 protein secreted significantly (p<0.05) lower 
amounts of IGF-I [14.21.8 ng/10 mg tissue; 14.3±2.4 
ng/10 mg tissue; 14.0±2.4 ng/10 mg tissue respectively 
in 0–10%; 10–50% and 50–80% cells with P53 protein 
IHCR positive explants vs. 24.1± 4.0 ng/10 mg tissue in 
explants with lack of cells with P53 protein IHC posi-
tive reaction. The lowest secretion of IGF-I [10,6±1.05 
ng/10mg of tissue] was observed in explants showing 
the highest rate (80–100%) of cells with positive IHCR 
to P53 protein (Figure 2).
The local secretion of IGFBP-3 was the lowest 
by explants with the highest rate of P53 protein IHC 
positive cells (80–100%) [8.8±1.0ng/10mg of tissue]. 
The secretion of IGFBP-3 was higher by explants with 
50–79.9% of P53 protein IHC positive cells [11.1±1.3 
ng/10 mg of tissue vs 8.8±1.0ng/10mg of tissue; 
p<0.05]. The secretion of IGFBP-3 was the highest by 
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Fig. 1. Secretion of hGH by breast cancer explants in relation to 
ratio of cells with showing positive immunohistochemical 
reaction (IHCR) to P53 protein (**p<0.01).
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explants with ratio of P53 IHC positive cells lower than 
50% [15.1±1.1 ng/10mg of tissue; 14.1±1.4 ng/10 mg of 
tissue; 15.8±1.8 ng/10 mg of tissue respectively in 0%; 
0–9.9%; 10–49.9% of cells with positive IHCR for P53 
protein (Figure 3). 
The pattern of local IGFBP-2 secretion by explants 
with various rates of P53 IHC positive cells similarly 
follows the pattern of IGFBP-3 secretion. The lowest 
IGFBP-2 secretion was found by explants with the high-
est rate of P53 protein IHC positive cells (80–100%) 
[4.02±1.6 ng/10 mg of tissue]. The secretion of IGFBP-2 
was higher by explants with 50–79.9% of P53 protein 
IHC positive cells [8.0.1±1.8 ng/10 mg of tissue vs 
4.02±1.6 ng/10 mg of tissue; p<0.05]. The secretion of 
IGFBP-2 was the highest by explants with a ratio of P53 
IHC positive cells lower than 50% [20.8±1.8 ng/10 mg 
of tissue; 20.2±2.2 ng/10 mg of tissue; 24.5±2.6 ng/10 
mg of tissue respectively in 0%; 0–9.9%; 10–49.9% of 
cells with positive IHCR for P53 protein (Figure 4).
No correlation was noted between the local secretion 
of PRL and the ratio of cells with positive IHCR for P53 
protein (26.0 1.6; 24.41.4; 26.6 1.6p.; 25.7 1.5 ng/10 mg 
tissue respectively in 0–9.9%; 10–49.9%; 50–79.9% and 
80–100% of cells IHC positive for P53 protein vs. 23.5 
1.3 ng/10 mg tissue in explants with lack of IHC posi-
tive reaction for P53 protein cells (Figure 5).
DISCUSSION
The current results suggest no correlation between 
basic prolactin secretion by breast cancer explants and 
the level of the overexpression of P53 protein. Features 
like aggressiveness of the breast tumor, early disease 
relapse, metastases, patients with node negative breast 
cancer who have poor overall survival – also linked with 
increased level of P53 protein overexpression – were 
associated with hyperprolactinemia. However, there 
is limited direct evidence of the relationship between 
local prolactin secretion by breast malignant tissue and 
overexpression of p53. Fritsche et al. found that pro-
lactin induction of Stat 5 mediated transcription was 
repressed by P53 (Fritsche et al. 1998). Therefore, this 
makes the discussion of our results concerning the rela-
tionship between P53 overexpression and local prolac-
tin secretion difficult.
On the other hand, results of the present study clearly 
showed a distinct difference in basic secretion of hGH 
and IGF-I by human breast cancer explants in relation 
to the ratio of cells with positive immunohistochemical 
reaction for P53 protein. Basic hGH secretion by breast 
cancer explants – having no cells with positive IHCR 
for P53 protein – was three times lower compared to 
those with overexpression of P53 protein. This obser-
vation may explain the clinically known phenomenon 
of poor prognosis for patients with high level of P53 
protein overexpression. Wild-type P53 is a tumour 
suppressor gene that plays a central role in maintain-
ing the genetic integrity of the cell by preventing cells 
with damaged DNA from further proliferation. Breast 
cancer cells that lack a wild-type functional form of P53 
protein, do not undergo apoptosis. One of the features 
of hGH is its antiapoptotic activity. Specific P53 gene 
mutations have been associated with poor prognosis in 
breast cancer patients. According to our present obser-
vation, the growth of malignant tissue with a low level 
of p53 gene control (high level of overexpression) seems 
to be powered by locally secreted hGH. Mutations in 
the P53 gene or overexpression of P53 protein is also of 
value in the prediction of beneficial effects of adjuvant 
radiotherapy or chemotherapy in breast cancer. These 
types of treatment reduce the production of hGH. This 
may further support the role of hGH in the develop-
ment of breast cancer.
Elledge et al. showed that the patient with a high 
ratio of cells immunohistochemically positive for P53 
protein had shorter survival time compared to patients 
with lack of or low ratio of such cells (Elledge et al. 
1994). In cancer cells that bear a mutant p53, this pro-
tein is no longer able to control cell proliferation, which 
results in inefficient DNA repair and the emergence of 
genetically unstable cells. The lack of control of prolif-
eration may result from an increased secretion of hGH.
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Fig. 2. Secretion of IGF-I by breast cancer explants in relation to 
ratio of cells with showing positive immunohistochemical 
reaction (IHCR) to P53 protein (**p<0.05).
Fig. 3. Secretion of IGFBP-3 by breast cancer explants in relation 
to ratio of cells with showing positive immunohistochemical 
reaction (IHCR) to P53 protein (*p<0.05).
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There is a growing body of evidence supporting that 
locally produced IGF-I in breast tissue mediates the GH 
stimulated growth of breast tumours and, therefore, it 
is suggested to be one of the breast cancer development 
risk factors. On the contrary, the role of circulating 
IGF-I in breast cancer development remains uncer-
tain. Our previous study showed hGH stimulation of 
local IGF-I secretion by human breast cancer explants. 
The disruption of normal interaction between P53 and 
IGF-mediated signal pathways can accelerate mam-
mary tumorigenesis. IGFs have been shown to protect 
cells from apoptosis through an IGF-I receptor medi-
ated cell survival pathway (Werner et al. 1996). Both 
the effects of a decrease in the number of IGF-receptors 
causing massive apoptosis and the overexpression of 
IGF receptors protecting cells from apoptosis have been 
demonstrated in vivo. A mutant version of P53 protein, 
commonly associated with malignant states, has been 
shown to derepress the IGF receptor promoter, with 
ensuing mitogenic activation by locally produced or 
circulating IGFs (Werner et al. 1996). The inability of 
mutant tumor suppressors to repress IGF-I receptor 
gene expression may result in increased levels of IGF-I 
receptor concentration and IGF binding which may 
lead to a reduction in apoptosis and enhanced survival 
capacity of malignant cells. 
Takahashi & Suzuki found that growth stimulation 
of MCF-7 breast neoplastic cells by IGF-I is accompa-
nied by tyrosine phosphorylation and nuclear exclusion 
of p53 (Takahashi & Suzuki 2003). Heron-Milhavet and 
Le Roitch showed that after 4-nitroquinoline 1-oxide-
induced DNA damage, IGF-I induced exclusion of the 
p53 protein from the nucleus and led to its degrada-
tion in the cytoplasm, whereas p53 mRNA was unaf-
fected. It is a novel role for IGF-I in the regulation of 
the MDM2/p53/p21 signaling pathway during DNA 
damage (Heron-Milhavet & Le Roitch 2002).
It may be hypothesized that the change in local secre-
tion of hGH and IGF-I is linked to the change in ratio 
of cells with positive IHCR for P53 protein. However, 
our current observation shows no significant change 
in basic secretion of hGH and IGF-I in correlation 
with the increase in ratio of cells with positive IHCR 
for P53 protein. The significant change was noted only 
between explants with and without cells with positive 
IHCR for P53 protein. In our present study, the basic 
secretion of IGF-I by explants lacking cells with positive 
IHCR for P53 protein is higher compared to those with 
overexpression of P53 protein. This result mirrors the 
pattern of hGH secretion by the same explants. Taking 
into account the well-known endocrine IGF-I/hGH 
negative feedback pathway, our present results seem to 
be plausible.
Hollowood et al. showed an auto/paracrine loop 
between IGFBP-3, one of components of IGF axis, and 
p53, which may provide control necessary to main-
tain normal tissue (Hollowood et al. 2000). IGFBP-3 
induction by P53 constitutes a new means of cross talk 
between the P53 and IGF axis. It may also suggest the 
ultimate function of IGFBP-3 as a protective factor 
against the potentially carcinogenic effects of hGH and 
IGF-I (Grimberg 2000). 
CONCLUSIONS
Our present data found that the influence of overex-
pression of P53 protein seems to be similar on local 
secretion of both IGFBP-3 and IGFBP-2. Our results 
showed an inverse relation between the ratio of cells 
with positive IHCR for P53 protein in breast cancer 
explants and secretion of IGFBP-2 and IGFBP-3. We 
also found the gradual decrease in secretion of these 
binding proteins with the increased ratio of cells immu-
nohistochemically postive for P53 protein. This phe-
nomenon was not clearly seen in regard to hGH and 
IGF-I secretion. A decrease in IGFBP-3 and IGFBP-2 
local secretion increases the level of free IGF-I that is 
available to its receptors. Observation by Werner et al. 
and Webster et al., that P53 regulates the expression of 
IGF-I-IR and IGFBP-3 suggests that there is a p53/IGF 
axis, whereby the increase in wild type P53 by DNA 
damage may induce apoptosis in part by down-regula-
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Fig. 4. Secretion of IGFBP-2 by breast cancer explants in relation 
to ratio of cells with showing positive immunohistochemical 
reaction (IHCR) to P53 protein (**p<0.05).
Fig. 5. Secretion of prolactin by breast cancer explants in relation 
to ratio of cells with showing positive immunohistochemical 
reaction (IHCR) to P53 protein.
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tion of the antiapoptotic effects of IGF-I (Werner et al. 
1996; Webster et al. 1996).
During mammary gland development, IGFBP-2 is 
expressed in the breast epithelial cells, while IGF-I is 
expressed in neighbouring stromal cells. IGFBP-2 is 
associated with apoptosis in the mammary gland at that 
stage. The exposure of breast cancer cell line Hs578T 
(which does not produce its own IGFBP-2) to exogenic 
IGFBP-2, increased p53 gene expression and showed 
the independence of IGF-I pro-apoptotic activity of 
IGFBP-2. Our recent results, which indicated the pro-
tective role of IGFBP-3 local secretion by breast cancer 
explants follows the observation of Grimberg (Grim-
berg 2000). Moreover, we also linked the changes in 
simultaneous, local secretion of IGFBP-3 and IGF-I, 
with tissue sex steroid receptor phenotype.
In conclusion, the presented data supports the 
hypothesis of the P53/hGH/IGF-I/IGFBP axis in breast 
cancer tissue. Furthermore, it also provides more evi-
dence supporting the presence of local tissue hGH/
IGF-I but not P53/PRL/IGF-I loop. These results should 
be considered preliminary, pending confirmation by 
other studies.
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